Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Feb 25;10(2):e003776. doi: 10.1136/jitc-2021-003776

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See https://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Pharmacokinetics and best percentage change in tumors. (A) Median concentration–time profiles for Q2W dosing regimens for SA ieramilimab. (B) Median concentration–time profiles for Q2W dosing regimens for ieramilimab in combination with spartalizumab. (C) Waterfall plot for best percentage change of predefined target lesions from baseline in sum of longest diameters based on local radiology review of RECIST V.1.1 for patients treated with ieramilimab +spartalizumab *Indicates the bars where best percentage change from baseline has been cut at 100%. CR, complete response; PD, progressive disease; PR, partial response; Q2W, every 2 weeks; Q4W, every 4 weeks; RECIST, Response Evaluation Criteria In Solid Tumors; SA, single agent; SD, stable disease.